BFA
NTLA icon

BlackRock Fund Advisors’s Intellia Therapeutics NTLA Stock Holding History

BlackRock Fund Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$9.23M Buy
704,350
+527,513
+298% +$7.93M ﹤0.01% 2614
2016
Q3 		$3.01M Buy
176,837
+13,069
+8% +$253K ﹤0.01% 3067
2016
Q2 		$3.5M Buy
+163,768
New +$4.36M ﹤0.01% 3011

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock Fund Advisors's NTLA Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Intellia Therapeutics (NTLA) stake by 298% in Q4 2016, buying an estimated $7.93M and bringing the position to 704,350 shares worth $9.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2614.

BlackRock Fund Advisors first reported a position in NTLA in Q2 2016 and has held it in 3 quarters since. 70 funds tracked by Wall St. Rank hold NTLA as of Q4 2016.

  • BlackRock Fund Advisors held 704,350 shares of Intellia Therapeutics worth $9.23M as of Q4 2016.
  • BlackRock Fund Advisors bought 527,513 Intellia Therapeutics shares in Q4 2016, an estimated $7.93M.
  • Intellia Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2614 holding.
  • BlackRock Fund Advisors first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 3 quarters since.
  • 70 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.